Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD) is a widespread diagnosis that affects many children and adolescents’ ability to function and succeed in academics, socially, or other situations. Non-stimulant medications have become widely utilized in this population, especially in stimulant-resistant individuals, whether due to poor efficacy or intolerance of side effects. However, these, too, harbor their own side effect profiles, including cardiovascular and sleep or energy level disturbances.
Objectives: We review the literature in discussion of the presentation and management of these adverse events for non-stimulant medications for ADHD, with a particular focus on atomoxetine and alpha agonists guanfacine and clonidine.
Conclusion: Non-stimulants are for the most part well tolerated but monitoring for cardiac and sleep difficulty is warranted.
Keywords: Mental health, children and adolescents, psychopharmacology, ADHD, attention deficit disorder, atomoxetine, alpha agonists.
Graphical Abstract
Current Psychopharmacology
Title:Adverse Effects of Non-Stimulant ADHD Drugs: Atomoxetine, Alpha-Agonists
Volume: 7
Author(s): Myrtha Gregoire-Bottex*Katherine Soe
Affiliation:
- Department of Pediatrics and Adolescent Medicine, Western Michigan University, Homer Stryker M.D. School of Medicine, 1000 Oakland Drive, Kalamazoo, Michigan, MI,United States
Keywords: Mental health, children and adolescents, psychopharmacology, ADHD, attention deficit disorder, atomoxetine, alpha agonists.
Abstract: Background: Attention-deficit/hyperactivity disorder (ADHD) is a widespread diagnosis that affects many children and adolescents’ ability to function and succeed in academics, socially, or other situations. Non-stimulant medications have become widely utilized in this population, especially in stimulant-resistant individuals, whether due to poor efficacy or intolerance of side effects. However, these, too, harbor their own side effect profiles, including cardiovascular and sleep or energy level disturbances.
Objectives: We review the literature in discussion of the presentation and management of these adverse events for non-stimulant medications for ADHD, with a particular focus on atomoxetine and alpha agonists guanfacine and clonidine.
Conclusion: Non-stimulants are for the most part well tolerated but monitoring for cardiac and sleep difficulty is warranted.
Export Options
About this article
Cite this article as:
Gregoire-Bottex Myrtha *, Soe Katherine , Adverse Effects of Non-Stimulant ADHD Drugs: Atomoxetine, Alpha-Agonists, Current Psychopharmacology 2018; 7 (1) . https://dx.doi.org/10.2174/2211556007666180328150248
DOI https://dx.doi.org/10.2174/2211556007666180328150248 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protonation States in Molecular Dynamics Simulations of Peptide Folding and Binding
Current Pharmaceutical Design Tropane and Nicotine Alkaloid Biosynthesis-Novel Approaches Towards Biotechnological Production of Plant-Derived Pharmaceuticals
Current Pharmaceutical Biotechnology ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology Changes in E-Selectin Levels Predict Carotid Stenosis Progression after Carotid Artery Stenting
Current Neurovascular Research Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease
Current Alzheimer Research Functional Activity and Connectivity Differences of Five Resting-State Networks in Patients with Alzheimer’s Disease or Mild Cognitive Impairment
Current Alzheimer Research Physiologically Based Mathematical Models to Optimize Therapies Against Metastatic Colorectal Cancer: A Mini-Review
Current Pharmaceutical Design sAPP Enhances the Transdifferentiation of Adult Bone Marrow Progenitor Cells to Neuronal Phenotypes
Current Alzheimer Research Neonatal Abstinence Syndrome Management: A Review of Recent Evidence
Reviews on Recent Clinical Trials Anti-cancer Potential of Phyto-alkaloids: A Prospective Review
Current Cancer Therapy Reviews Purinergic P2X Receptors: Structural and Functional Features Depicted by X-Ray and Molecular Modelling Studies
Current Medicinal Chemistry Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules
Current Drug Targets Inpatient Care of the HIV Infected Patient in the Highly Active Antiretroviral Therapy (HAART) Era
Current HIV Research Social Determinants of Childhood Obesity: Beyond Individual Choices
Current Pediatric Reviews Amyloid β Oligomers Decrease Hippocampal Spontaneous Network Activity in an Age-Dependent Manner
Current Alzheimer Research Editorial [Hot topic: Current Approaches for the Treatment of Cognitive Deficits in CNS Disease (Guest Editor: Robert L. Hudkins)]
Current Topics in Medicinal Chemistry Synergy Between Direct Coronary Stenting Technique and Use of the Novel Thin Strut Cobalt Chromium Skylor™ Stent: the Mace in Follow Up Patients Treated with Skylor Stent [MILES Study]
Current Cardiology Reviews Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design Design and Evaluation of a Modulated TENS Stimulation in Medical Pain Therapy
Current Signal Transduction Therapy Myelination in Bipolar Patients and the Effects of Mood Stabilizers on Brain Anatomy
Current Pharmaceutical Design